Our friend Bruce Beale was kind enough to Extract this marvelous news about our friends at Lilly from a recent issue of Fortune on the Fortune 500. Regrettably it omits the real biggies like Glaxo and Novo, but it shows quite how well Lilly and their shareholders are doing at our expense in an industry renowned for corruption.
| Awesome 1999 Performance by Lilly | |
| Company by ROE | Profit ROE |
| Eli Lilly | 54% |
| BMS | 48% |
| Merck | 44% |
| Schering-Plough | 41% |
| Amgen | 36% |
| Pfizer | 36% |
| Warner-Lambert | 34% |
| Abbott | 33% |
| Allergan | 30% |
| Johnson & Johnson | 26% |
| Pharmacia Upjohn | 14% |
| AHP | -20% |
| Company Alphabetic | Profit ROE |
| Abbott | 33% |
| AHP | -20% |
| Allergan | 30% |
| Amgen | 36% |
| BMS | 48% |
| Eli Lilly | 54% |
| Johnson & Johnson | 26% |
| Merck | 44% |
| Pfizer | 36% |
| Pharmacia Upjohn | 14% |
| Schering-Plough | 41% |
| Warner-Lambert | 34% |
| (ROE - Return on Equity) | |
| Revenues for 12 company group: $167.5 billion | |
| Profits for 12 company group: $ 27.3 billion | |
| Number of employees 518,256 | |
| Revenues per employee: $323,627 | |
| Profits per employee: $ 52,627 | |
| Profits as percent of sales: 16.3% | |